Vaccines for malaria, tuberculosis, Alzheimer’s disease, AIDS, pandemic flu, genital herpes, urinary tract infections and grass allergies could all be on the market in five years or less.
Once considered a low-profit corner of the drug industry, vaccines are enjoying a renaissance as the lure of big profits, advantages in technology and growing government support draws in new companies.
Contrasted with prescription drug sales—which are forecasted to rise by a third in five years—vaccine sales should double, from $19 billion last year to $39 billion in 2013. This rise can be attributed to the government’s list of recommended vaccines for children doubling in the past twenty-five years and improved technology for creating and mass producing vaccines.
About EQUITIES:
Since 1951, EQUITIES Magazine has been a leading media company providing business editorial content designed to serve the needs of business leaders, professionals, institutional investors and retail investors. We are focused on business and the business of making money, not on lifestyle subjects. We publish original reporting in print and on our website, as well as select content at www.nasdaq.com. For 28 years we have hosted our own branded investor conferences that connect public company CEO’s with our loyal readers in the investment community.
Sign up for a free one-year subscription to EQUITIES Magazine
